Analysts Offer Insights on Healthcare Companies: Dr Reddy’s Laboratories (RDY) and Genmab (GMAB)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dr Reddy’s Laboratories (RDY) and Genmab (GMAB) with bullish sentiments.
Dr Reddy’s Laboratories (RDY)
Bank of America Securities analyst Neha Manpuria maintained a Buy rating on Dr Reddy’s Laboratories today. The company’s shares closed last Monday at $13.81.
Manpuria has an average return of
According to TipRanks.com, Manpuria is ranked #5988 out of 12539 analysts.
Dr Reddy’s Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $14.34, which is a 5.5% upside from current levels. In a report issued on October 12, Exane BNP Paribas also upgraded the stock to Buy with a $14.80 price target.
See today’s best-performing stocks on TipRanks >>
Genmab (GMAB)
In a report released today, Charlie Haywood from Bank of America Securities reiterated a Buy rating on Genmab. The company’s shares closed last Monday at $44.77.
Haywood has an average return of
According to TipRanks.com, Haywood is ranked #2342 out of 12539 analysts.
Genmab has an analyst consensus of Strong Buy, with a price target consensus of $101.23, implying a 126.0% upside from current levels. In a report issued on October 24, TipRanks – DeepSeek also upgraded the stock to Buy with a $48.00 price target.
Read More on RDY:
Disclaimer & DisclosureReport an Issue
- Dr. Reddy’s Files Unmodified Auditor Review on September 2026 Interim Results
- Dr. Reddy’s Files Form 6-K, Publishes Q2 FY27 Earnings Call Recordings
- Improving Margins and EPS Upgrades Offset by Full Valuation, Supporting Hold Rating
- Dr. Reddy’s upgraded to Hold from Underperform at Jefferies
- Dr. Reddy’s upgraded to Neutral from Underweight at JPMorgan
